With the main benchmarks hovering near record levels in the wake of a solid jobs report, a key payrolls data showed the economy added 214,000 jobs in October, while the unemployment rate ticked down to 5.8% — a broadly positive reading.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)’s shares soared as much as $20.62, hitting $325.13, or 6.77 percent as the company received one good news after the next.

Regeneron’s shares are predicted to rise tomorrow as the company received the FDA approval of EYLEA (aflibercept) injection for the treatment of diabetic macular edema (DME) – a common complication in the eyes of diabetic patients.

Due to its capacity to self-renew and give rise to cells of various lineage, mesenchymal stem cells (MSCs) have generated a great amount of enthusiasm as a novel therapeutic paradigm for a variety of diseases.